These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19707954)

  • 21. An open study of risperidone liquid in the acute phase of schizophrenia.
    Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
    Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.
    Chawla B; Luxton-Andrew H
    Hum Psychopharmacol; 2008 Apr; 23(3):211-6. PubMed ID: 18219624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.
    Ciudad A; Montes JM; Olivares JM; Gómez JC;
    Eur Psychiatry; 2004 Sep; 19(6):358-65. PubMed ID: 15363475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.
    Centorrino F; Meyers AL; Ahl J; Cincotta SL; Zun L; Gulliver AH; Kinon BJ; Houston JP
    Hum Psychopharmacol; 2007 Oct; 22(7):455-62. PubMed ID: 17708578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia.
    Chue P; Jones B; Taylor CC; Dickson R
    Can J Psychiatry; 2002 Oct; 47(8):771-4. PubMed ID: 12420656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New formulations of olanzapine in the treatment of acute agitation].
    Bartkó G
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):171-8. PubMed ID: 17211052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine treatment of residual positive and negative symptoms.
    Buchanan RW; Ball MP; Weiner E; Kirkpatrick B; Gold JM; McMahon RP; Carpenter WT
    Am J Psychiatry; 2005 Jan; 162(1):124-9. PubMed ID: 15625210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.
    Lambert M; Huber CG; Naber D; Schacht A; Wagner TT; Hundemer HP; Karow A; Schimmelmann BG
    Pharmacopsychiatry; 2008 Sep; 41(5):182-9. PubMed ID: 18763220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
    Normann C; Schmauss M; Bakri N; Gerwe M; Schreiner A
    Pharmacopsychiatry; 2006 Nov; 39(6):209-12. PubMed ID: 17124642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.
    Kopelowicz A; Zarate R; Tripodis K; Gonzalez V; Mintz J
    Am J Psychiatry; 2000 Jun; 157(6):987-93. PubMed ID: 10831481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
    Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
    J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.
    Arranz B; San L; Dueñas RM; Centeno M; Ramirez N; Salavert J; Del Moral E
    Hum Psychopharmacol; 2007 Jan; 22(1):11-5. PubMed ID: 17191265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.
    Baker RW; Kinon BJ; Maguire GA; Liu H; Hill AL
    J Clin Psychopharmacol; 2003 Aug; 23(4):342-8. PubMed ID: 12920409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.
    Hatta K; Kawabata T; Yoshida K; Hamakawa H; Wakejima T; Furuta K; Nakamura M; Hirata T; Usui C; Nakamura H; Sawa Y
    Gen Hosp Psychiatry; 2008; 30(4):367-71. PubMed ID: 18585542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label study of olanzapine in children and adolescents with schizophrenia.
    Quintana H; Wilson MS; Purnell W; Layman AK; Mercante D
    J Psychiatr Pract; 2007 Mar; 13(2):86-96. PubMed ID: 17414684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.